Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 17/20 | 0.86 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.65 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.65 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152080 | 0.92 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2153213 | 0.92 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2152051 | 0.85 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2179977 | 0.83 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2152856 | 0.82 | GRIA2 (0.80) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2152720 | 0.82 | GRIA2 (1.00) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2774819 | 0.82 | GRIA2 (0.79) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL2775612 | 0.81 | GRIA2 (0.62) | GRIA2GRIA1GRIA3GRIA4 | |
| SCHEMBL5185245 | 0.80 | GRIA2 (0.84) | GRIA2 | |
| SCHEMBL2161138 | 0.79 | GRIA2 (0.82) | GRIA2GRIA1GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011083265-A1 | NOVEL DERIVATIVES OF CYCLOPROPYLATED BENZOTHIADIAZINES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-07-14 | — | — | WO | disclosed |
| EP-2147915-B1 | New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2010-09-15 | — | — | EP | disclosed |
| US-7741320-B2 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-06-22 | — | — | US | disclosed |
| EP-2147915-A1 | New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2010-01-27 | — | — | EP | disclosed |
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | LES LABORATOIRES SERVIER (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | ACLY, HCAR1, GABRG1 | GRIA2 116/4885GRIA1 68/4885GRIA3 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.